- Imagene AI has entered into a collaboration with Daiichi Sankyo to advance biomarker discovery and response prediction across oncology drug development programs
- Under the collaboration, Daiichi Sankyo will leverage Imagene’s OI Suite, powered by the CanvOI foundation model, to integrate H&E and IHC whole-slide images with molecular and clinical data to enhance biomarker identification and patient stratification
- The partnership will support select ADC programs using AI-driven response prediction models and Composite Continuous Scoring to evaluate target expression, leveraging a multimodal real-world data lake of >3.5M tissue samples
Ref: Imagene AI | Image: Imagene AI | Press Release
Related News: Imagene Partners with Tempus AI to Develop AI-Powered Diagnostics for NSCLC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
